Addressing Advances and Roadblocks in Lipid Management, With Joseph Saseen, PharmD

7 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Dyslipidemia is an increasingly prevalent cardiovascular risk factor worldwide, and current therapies are rapidly evolving to keep up with the spread of increased hypertriglyceridemia, hypercholesterolemia, and low HDL-C.
On National Lipid Day 2026, the editorial team at HCPLive spoke with Joseph Saseen, PharmD, professor and associate dean for clinical affairs at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Science and former president of the National Lipid Association, to discuss recent advancements in the field and how far we have yet to go.
“The medicines, at least the foundational medicines, are very affordable, if not free under some insurance plans,” Saseen told HCPLive. “Basic treatment is not costly. It does require a commitment by the provider and by the patient to not only adhere with the prescribed regimen, but more importantly, to buy into the regimen through shared decision-making, through conversations that discuss cardiovascular risk, to motivate the patient to understand the risks associated with elevated LDL-C and getting that commitment to treat.”

Read the full article here: https://www.hcplive.com/view/addressing-advances-and-roadblocks-in-lipid-management-with-joseph-saseen-md

Key Timestamps
00:00:01 Intro
00:00:08 Balancing LDL-C Management
00:01:44 Lp(a) screening
00:02:57 Obicetrapib and CETP inhibitors
00:04:28 Familial hypercholesterolemia
00:05:38 Failure to meet LDL-C goals
00:08:35 Lipid management misconceptions
00:10:04 Looking ahead

#cardiology #lipids #dyslipidemia
Categoria
Cardiology
Commenta per primo questo video.

Prossimo